Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

immunoglobulin g - human -

Kanada - Inggeris - Health Canada

csl behring canada inc - immunoglobulin (human) - solution - 120g - immunoglobulin (human) 120g - serums

Singapura - Inggeris - HSA (Health Sciences Authority)

siemens healthcare pte. ltd. - immunology - n antiserum to human α2-macroglobulin is an in vitro diagnostic reagent for the quantitative, ifcc standardized determination of α2-macroglobulin as aid to differential diagnosis of hematuria in patients with signs or suspicion of kidney disorders in human urine by means of automated siemens healthineers immuno-nephelometry systems. additionally, n antiserum to human α2-macroglobulin can be used as aid to diagnosis of hyperfibrinolysis, acute pancreatitis and nephrotic syndrome in human serum and heparin plasma.

Singapura - Inggeris - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - clinical chemistry - in vitro diagnostic reagent for the quantitative determination of alpha2‑macroglobulin in samples of human origin (serum, urine) by immunoturbidimetry on the cobas c 501/502 automated clinical chemistry analyzers.

Singapura - Inggeris - HSA (Health Sciences Authority)

the binding site pte. ltd. - clinical chemistry - the optilite alpha-2-macroglobulin kit is intended for the quantitative in vitro measurement of alpha-2-macroglobulin in serum, edta plasma and lithium heparin plasma using the binding site optilite analyser to aid in the diagnosis of blood-clotting or clot lysis disorders. this test should be used in conjunction with other laboratory and clinical findings.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastic agents - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy.brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Israel - Inggeris - Ministry of Health

mediline ltd. - immunoglobulin normal human 1 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

Israel - Inggeris - Ministry of Health

mediline ltd. - immunoglobulin normal human 6 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

Israel - Inggeris - Ministry of Health

mediline ltd. - immunoglobulin normal human 3 g/vial - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinaemia or hypogammaglobulinaemia). idiopathic thrombocytopenic purpura (itp).

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

csl behring gmbh - immunoglobulin human polyvalentes 6000 mg - powder for solution for injection - 6 g - human polyvalent immunoglobulin 6000 mg - immunoglobulins, normal human, for intravascular adm.